一例来那度胺依赖型骨髓增生异常综合征
A case of lenalidomide-dependent myelodysplastic syndrome.
作者信息
Miller Ira J, Hsu Wei-Tong, Weisberger James, Venugopal Parameswaran
机构信息
Department of Pathology, Rush University Medical Center, Chicago, IL.
BioReference Laboratories, Elmwood Park, NJ; and.
出版信息
Blood Adv. 2017 Jun 30;1(16):1238-1242. doi: 10.1182/bloodadvances.2017006114. eCollection 2017 Jul 11.
Abstract
A man with cytopenias, dysplasia, excess blasts, P53 and RUNX1 mutations, and ring chromosome 7 recovered after stopping lenalidomide.
摘要
一名患有血细胞减少、发育异常、原始细胞增多、P53和RUNX1突变以及7号环状染色体的男性在停用来那度胺后康复。
相似文献
1
A case of lenalidomide-dependent myelodysplastic syndrome.
Blood Adv. 2017 Jun 30;1(16):1238-1242. doi: 10.1182/bloodadvances.2017006114. eCollection 2017 Jul 11.
2
The role of lenalidomide in the treatment of patients with chromosome 5q deletion and other myelodysplastic syndromes.
Curr Opin Hematol. 2007 Mar;14(2):123-9. doi: 10.1097/MOH.0b013e328016847a.
3
Myelodysplastic syndromes.
Lancet. 2014 Jun 28;383(9936):2239-52. doi: 10.1016/S0140-6736(13)61901-7. Epub 2014 Mar 21.
4
Treatment of Patients With Myelodysplastic Syndrome With Lenalidomide in Clinical Routine in Austria.
Clin Lymphoma Myeloma Leuk. 2015 Nov;15(11):e143-9. doi: 10.1016/j.clml.2015.07.645. Epub 2015 Aug 5.
5
The role of lenalidomide in the management of myelodysplasia with del 5q.
Br J Haematol. 2008 Feb;140(3):267-78. doi: 10.1111/j.1365-2141.2007.06910.x.
6
Molecular mechanisms that produce secondary MDS/AML by RUNX1/AML1 point mutations.
J Cell Biochem. 2011 Feb;112(2):425-32. doi: 10.1002/jcb.22974.
7
Myelodysplastic syndromes with 5q deletion: pathophysiology and role of lenalidomide.
Ann Hematol. 2014 May;93(5):723-33. doi: 10.1007/s00277-014-2022-3. Epub 2014 Mar 14.
8
Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion.
Br J Haematol. 2014 Jul;166(2):189-201. doi: 10.1111/bjh.12876. Epub 2014 Apr 10.
9
10
Treatment of the 5q- syndrome.
Hematology Am Soc Hematol Educ Program. 2006:192-8. doi: 10.1182/asheducation-2006.1.192.
引用本文的文献
1
Lenalidomide-associated B-cell ALL: clinical and pathologic correlates and sensitivity to lenalidomide withdrawal.
Blood Adv. 2023 Jul 11;7(13):3087-3098. doi: 10.1182/bloodadvances.2022009212.
本文引用的文献
1
Multiple myeloma cells' capacity to decompose HO determines lenalidomide sensitivity.
Blood. 2017 Feb 23;129(8):991-1007. doi: 10.1182/blood-2016-09-738872. Epub 2016 Dec 27.
2
Therapy-related myeloid neoplasms.
Curr Opin Hematol. 2017 Mar;24(2):152-158. doi: 10.1097/MOH.0000000000000316.
3
Maintenance Therapy With Immunomodulatory Drugs in Multiple Myeloma: A Meta-Analysis and Systematic Review.
J Natl Cancer Inst. 2015 Nov 18;108(3). doi: 10.1093/jnci/djv342. Print 2016 Mar.
4
Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia.
Nature. 2015 Feb 26;518(7540):552-555. doi: 10.1038/nature13968. Epub 2014 Dec 8.
5
Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma.
Blood. 2014 Jul 24;124(4):536-45. doi: 10.1182/blood-2014-02-557819. Epub 2014 Jun 9.
6
Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells.
Science. 2014 Jan 17;343(6168):301-5. doi: 10.1126/science.1244851. Epub 2013 Nov 29.
7
The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins.
Science. 2014 Jan 17;343(6168):305-9. doi: 10.1126/science.1244917. Epub 2013 Nov 29.
8
Dexamethasone and lenalidomide have distinct functional effects on erythropoiesis.
Blood. 2011 Aug 25;118(8):2296-304. doi: 10.1182/blood-2010-11-318543. Epub 2011 Apr 28.
9
Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy.
Br J Haematol. 2007 Sep;138(5):640-3. doi: 10.1111/j.1365-2141.2007.06698.x.
10
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Blood. 2006 Nov 15;108(10):3458-64. doi: 10.1182/blood-2006-04-015909. Epub 2006 Jul 13.
Zotero 插件